Oncology

Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.

ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies

Determining what to measure, and how best to measure it, can be surprisingly complex-and appropriate metrics can vary between cancer types and patient populations.

At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.

A value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.

Participants in a new CMS payment program will attempt to improve the effectiveness and efficiency of cancer care delivery. Here’s how.

Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here’s how. Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here's how.

AML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents

Caring for survivors and finding best practices for new treatments

How plans can achieve the right balance between cost and outcomes